Louis Pisters

Professor of Urology

The University of Texas MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Purpose: Sequential high-dose chemotherapy (HDC) using carboplatin/etoposide with autologous stem cell transplant can be curative in relapsed germ cell tumors (GCT). However, outcomes are poor for multiply relapsed/refractory tumors. We studied gemcitabine/docetaxel/melphalan/carboplatin (GemDMC), which exploits DNA damage repair inhibition. We hypothesized that concurrent bevacizumab, targeting the high vascularity of GCT, would synergize with HDC. Patients and Methods: Trial eligibility included second or later relapse or poor-risk first relapse and adequate end-organ function. Treatment consisted of sequential bevacizumab–GemDMC (HDC cycle 1) and bevacizumab–ifosfamide/carboplatin/etoposide (C2) in three consecutive cohorts: bevacizumab/full-dose GemDMC (cohort 1), bevacizumab/reduced-dose GemDMC (cohort 2), and no bevacizumab/reduced-dose GemDMC (cohort 3). The trial was powered to distinguish a target 50% 2-year relapse-free survival rate from an expected <25%. We validated its results in an off-trial fourth cohort treated the same as cohort 3. Results: We treated 165 male patients (65 trial and 100 cohort 4 patients), after a median of three prior therapy lines, mostly with cisplatin-refractory tumors at relapse (45% refractory and 23% absolutely refractory) and 19% primary mediastinal tumors. The overall response rate was 84.5% (77% complete response/partial response with negative markers). The treatment-related mortality rates in cohorts 1 to 4 were 13%, 8%, 4%, and 4%, respectively. Resection of residual lesions in 74 patients found no viable GCT in 76%. The 5-year relapse-free survival and overall survival rates were 57.1% and 58.3%, respectively, without differences between trial and cohort 4 patients or between patients receiving bevacizumab (cohorts 1 and 2) and those not receiving it (cohorts 3 and 4). Conclusions: Sequential GemDMC–carboplatin/etoposide with or without ifosfamide shows outcomes that exceed the anticipated results in multiply, poor-risk relapsed GCT. Bevacizumab did not improve outcomes. See related commentary by Kollmannsberger et al., p. 257

Year:

2025

Purpose: Develop and deploy a robust discovery platform that encompasses heterogeneity, clinical annotation, and molecular characterization and overcomes the limited availability of prostate cancer models. This initiative builds on the rich MD Anderson (MDA) prostate cancer (PCa) patient-derived xenograft (PDX) resource to complement existing publicly available databases by addressing gaps in clinically annotated models reflecting the heterogeneity of potentially lethal and lethal prostate cancer. Experimental Design: We performed whole-genome, targeted, and RNA sequencing in representative samples of the same tumor from 44 PDXs derived from 38 patients linked to donor tumor metadata and corresponding organoids. The cohort includes models derived from different morphologic groups, disease states, and involved organ sites (including circulating tumor cells), as well as paired samples representing heterogeneity or stages before and after therapy. Results: The cohort recapitulates clinically reported alterations in prostate cancer genes, providing a data resource for clinical and molecular interrogation of suitable experimental models. Paired samples displayed conserved molecular alteration profiles, suggesting the relevance of other regulatory mechanisms (e.g., epigenomic) influenced by the microenvironment and/or treatment. Transcriptomically, models were grouped on the basis of morphologic classification. DNA damage response–associated mechanisms emerged as differentially regulated between adenocarcinoma and neuroendocrine prostate cancer in a cross-interrogation of PDX/patient datasets. Conclusions: We addressed the gap in clinically relevant prostate cancer models through comprehensive molecular characterization of MDA PCa PDXs, providing a discovery platform that integrates with patient data and benchmarked to therapeutically relevant consensus clinical groupings. This unique resource supports robust hypothesis generation and testing from basic, translational, and clinical perspectives.

Year:

2024

Purpose: Develop and deploy a robust discovery platform that encompasses heterogeneity, clinical annotation, and molecular characterization and overcomes the limited availability of prostate cancer models. This initiative builds on the rich MD Anderson (MDA) prostate cancer (PCa) patient-derived xenograft (PDX) resource to complement existing publicly available databases by addressing gaps in clinically annotated models reflecting the heterogeneity of potentially lethal and lethal prostate cancer. Experimental Design: We performed whole-genome, targeted, and RNA sequencing in representative samples of the same tumor from 44 PDXs derived from 38 patients linked to donor tumor metadata and corresponding organoids. The cohort includes models derived from different morphologic groups, disease states, and involved organ sites (including circulating tumor cells), as well as paired samples representing heterogeneity or stages before and after therapy. Results: The cohort recapitulates clinically reported alterations in prostate cancer genes, providing a data resource for clinical and molecular interrogation of suitable experimental models. Paired samples displayed conserved molecular alteration profiles, suggesting the relevance of other regulatory mechanisms (e.g., epigenomic) influenced by the microenvironment and/or treatment. Transcriptomically, models were grouped on the basis of morphologic classification. DNA damage response–associated mechanisms emerged as differentially regulated between adenocarcinoma and neuroendocrine prostate cancer in a cross-interrogation of PDX/patient datasets. Conclusions: We addressed the gap in clinically relevant prostate cancer models through comprehensive molecular characterization of MDA PCa PDXs, providing a discovery platform that integrates with patient data and benchmarked to therapeutically relevant consensus clinical groupings. This unique resource supports robust hypothesis generation and testing from basic, translational, and clinical perspectives.

Year:

2024

Collaborators (12)

Matthew Campbell

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

John Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jean-Nicolas Vauthey

Professor of Surgery

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nora M. Navone

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paul Corn

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yago Nieto

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sumit Subudhi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

john Davis

Associate Professor

MD Anderson Cancer Center

UNITED STATES
View details

John Ward

Professor

MD Anderson Cancer Center

UNITED STATES
View details